🧪 Priority ahead: A strong push to reach 240 patients in the #ALBTRIAL - crucial for robust clinical validation and real patient impact

🏆 And congratulations to Aleksander Krag on the #HagedornPrize for groundbreaking work in early detection of #LiverDisease - an inspiration to the whole consortium

👏 Huge thanks to the SC + all team members for open discussions and constructive feedback. Now it’s time to roll up our sleeves & push hard toward the project finish line (Sept 2026). Delivering high-quality outputs to our funding agency (EU) is ambitious but absolutely achievable. We can do it! 🏃‍♀️🏃‍♂️

Across all WPs, we saw impressive progress - from clinical and genetic characterisation to #microbiome, multi #omics, experimental validation & systems #modelling. Major advances in #proteomics, #metabolomics, #biomarkers & prediction models - highlight the power of our multidisciplinary team. 🔬

Prices:
€60 €
45 - Students, unemployed, pensioners, over 65s, Friends of the CCCB

Registrations:
Course offered in both in-person and online formats. Register here .

👉 In this video, Dávid Tornai (MD, PhD) from Maria Papp's group at the University of Debrecen in Hungary presents the consortium's research on serum #villin-1, a tell-tale sign of #GutBarrier failure in cirrhotic patients with acute #decompensation via a graphical abstract.

📽️ youtu.be/URerer6AxxY

The session will also be available to watch on demand on EASL Campus from Thursday, 27 November

👉 easlcampus.eu/easl-studio/...

Within MICROB-PREDICT, WP6 is uncovering the mechanisms by which rifaximin & albumin interact with the microbiome and the gut–liver axis, using cellular + rodent models.

🔬 Read the original publication by Boglarka Balogh, David Tornai, Aniko Csillag et al. (2025) on behalf of the MICROB-PREDICT consortium and the PREDICT study group of the EASL-CLIF consortium: onlinelibrary.wiley.com/doi/10.1111/...

Both groups (placebo vs. #albumin treatment) are monitored closely regarding their liver disease & overall health. We thank the dedicated teams at all sites across Europe for their hard work in achieving this milestone. We look forward to continuing this progress toward completing the ALB-TRIAL! 💪

The ALB-TRIAL is a double-blinded, placebo-controlled clinical trial to see if a new biomarker can be used to predict which patients with #cirrhosis + #ascites benefit most from long-term human #albumin infusion. Moving towards personalised treatment, less complications & lower risk of death. 🔬⚕️🩺